KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEquity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Takeda Pharmaceutical (TAK) Income from Non-Controlling Interests (2025 - 2026)

Takeda Pharmaceutical has reported Income from Non-Controlling Interests over the past 2 years, most recently at $7.7 million for Q1 2026.

  • For Q1 2026, Income from Non-Controlling Interests rose 31.31% year-over-year to $7.7 million; the TTM value through Mar 2026 reached $7.7 million, up 31.31%, while the annual FY2026 figure was $8.0 million, 36.58% up from the prior year.
  • Income from Non-Controlling Interests was $7.7 million for Q1 2026 at Takeda Pharmaceutical, up from -$649790.1 in the prior quarter.
  • Across five years, Income from Non-Controlling Interests topped out at $7.7 million in Q1 2026 and bottomed at -$649790.1 in Q4 2025.